Job title: Senior Scientist
I got my degree at Boston University in 2013. I then trained under Dr. Francisco Quintana at Brigham and Women’s Hospital for 3 and a half years where my work focused on understanding mechanisms of tolerogenic dendritic cell induction, regulation of innate immune cell activation in the central nervous system, and development of nanoparticle therapeutics. In 2016, when Dr. Quintana co-founded AnTolRx, I became its first employee. Since then, I have led 3 pre-clinical research programs aimed at validating AnTolRx’s antigen-specific platform to promote tolerance in autoimmune diseases including Type 1 Diabetes and Multiple Sclerosis.
Activation of the Aryl Hydrocarbon Receptor by Antigen-Specific Tolerogenic Nanoparticles for the Treatment of Autoimmune Diseases 4:30 pm
Targeted activation of the Aryl Hydrocarbon Receptor induces FoxP3+ and IL10+Regulatory T cells Antigen-specific nano-liposomes targeting dendritic cells induces tolerance and suppresses disease in multiple pre-clinical mouse models AhR activation by liposomes suppresses pro-inflammatory signaling pathways in tissue-resident innate immune cellsRead more
day: Day Two